Followers | 31 |
Posts | 2649 |
Boards Moderated | 0 |
Alias Born | 10/28/2013 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, June 17, 2016 9:08:08 AM
"I can imagine what a nightmare it could have been for NWBO if BP or the shorts had yanked the strings of their manufacturer to turn them away at a critical moment. That kind of loyalty money can't buy."
------------------------------------------------------------------
This is exactly how I see it. You look at the Phase V article, for example, and you know there is a force out there trying to ruin the company. Having mfg with a fully independent company just isn't an option, and never was if LP anticipated this kind of aggression.
That doesn't mean that any improper dealings between NWBO and Cognate are OK, but for me, it means I don't care about the small stuff.
As for why the two companies could not be one... I do think LP sees Cognate as the sure thing if immunotherapies are the future, while NWBO is the horse in the race, with an enormous possible payoff. I don't think that is a horrible attitude, I think it is just rational. Even from an ethical standpoint, if she can provide affordable mfg to immunotherapy companies, then she will have done something good. Pyrrhonian would gag at the sound of that given the apparent enormous cost per patient that Cognate has charged, but we do not know yet how much money went into automated mfg development, etc.. Again, I don't care about the small stuff, but the big stuff does matter, so I sure hope to hear some explanation for those costs someday soon.
How to rationalize the lack of transparency on the enormous $ to Cognate?
1) If LP spent a ton of $ on automated mfg development, and then such was not successful, that would look very bad. Not a great reason, but a reason.
2) Making such info public would help competitors strategize.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM